2013


To access this material please log in or register

Register Authorize
2013/№4

Long-term atorvastatin therapy in patients with ischemic heart disease: effect on glycemia and local vascular stiffness

Koshelskaya O. A., Sushkova A. S., Suslova T. E., Ogurkova O. N., Karpov R. S.
Federal State Budgetary Institution, “Research Institute of Cardiology” at the Siberian Branch of Russian Academy of Medical Sciences, Kievskaya 111a, Tomsk 634012

Keywords: arterial stiffness, atorvastatin, coronary heart disease, treatment, diabetes mellitus, subclinical inflammation

DOI: 10.18087/rhj.2013.4.1820

Background. Large-scale studies of recent years have demonstrated that statins, including atorvastatin, can produce a diabetogenic effect and increase the incidence of borderline glycemia. Aim. Studying lipid and anti-inflammatory effects of long-term (9–12 months) atorvastatin therapy and effects of this therapy on carbohydrate metabolism and local vascular stiffness in patients with IHD and DM. Materials and methods. 20 patients with type 2 DM were included in the study. One third of these patients had documented IHD with stable angina and 14 patients had IHD without carbohydrate metabolic disorders. Time courses of blood lipid transport, carbohydrate metabolism, inflammation markers, and common carotid artery (CCA) ultrasound elasticity indices were evaluated during the atorvastatin treatment. Results. In the course of atorvastatin treatment (mean dose, 15.3 mg / day), LDL–C values decreased by 44 % with no changes in apoB / apoA-1. Median hsСRP values decreased from 5.7 (2.5–9.1) to 0.98 (0.5–2.5) mg / l (р<0.05). Basal glycemia and HbA increased from 7.0±0.3 to 7.2±0.3 % (р<0.05) and the CCA wall compliance index decreased from 31.6±1.9×10–3 kPa to 28.4±1.4×10–3 kPa (p<0.01). Conclusion. In patients with IHD and DM, the atorvastatin therapy at the mean dose of 15.3 mg / day exerts pronounced lipid-lowering and anti-inflammatory effects; however at 9–12 months, this therapy is associated with mild hyperglycemia and with increased local stiffness of great arterial walls.
  1. European Association for Cardiovascular Prevention & Rehabilitation. ESC / EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32 (14):1769–1818.
  2. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. Российский кардиологический журнал. 2012;4 (96). Приложение I:1–32.
  3. van Popele NM, Grobbee DE, Bots ML et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 2001;32 (2):454–460.
  4. Dilaveris P, Giannopoulos G, Riga M et al. Beneficial effect of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Phamacol. 2007;5 (3):227–237.
  5. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364 (9435):685–696.
  6. Insull W, Kafonek S, Goldner D. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin at six weeks. ASSET Investigators. Am J Cardiol. 2001;87 (5):554–559.
  7. Cannon CP, Braunwald E, McCabe CH et al? for Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350 (15):1495–1504.
  8. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of ator­vastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering): a randomized controlled trial. JAMA. 2001;285 (13):1711–1718.
  9. Jones PH, McKenney JM, Karalis DG. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evide. Based Cardiovasc Med. 2005;9 (2):98–101.
  10. Souza-Costa DC, Sandrim VC, Lopes LF et al. Anti-inflammatory effects of atorvastatin:modulation by the T-786C polymorphism in the endothelial nitric oxide syntase gene. Atherosclerosis. 2006;197 (1):467–468.
  11. Сусеков А. В., Зубарева М. Ю., Трипотень М. И. и др. Рандомизированное исследование «ФАРВАТЕР». Часть 1. Влияние аторвастатина 10–20 мг / сут. На уровень липидов, С-реактивного белка и фибриногена у больных ишемической болезнью сердца и дислипидемией. Кардиология. 2006;46 (9):4–10.
  12. Castro PF, Miranda R, Verdejo HE et al. Pleiotropic effects of atorvastatin in heart failure:role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant. 2008;27 (4):435–441.
  13. Koh KK, Quon M, Han SH et al. Atorvastatin worsens glucose metabolism and insulin sensitivity in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55 (12):1209–1216.
  14. Priess D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305 (24):2556–2564.
  15. Sattar N, Preiss D, Murray HM et al. Statin and risk of incident diabetes:a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375 (9716):735–742.
  16. Rajpathak SN, Kumbhani DJ, Crandall J et al. Statin Therapy and Developing Type 2 Diabetes:a meta-analysis. Diabetes Care. 2009;32 (10):1924–1929.
  17. Touboul PJ, Hennerici MG, Meairs S et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23 (1):75–80.
  18. Hayashi K, Handa H, Nagasawa S et al. Stiffness and elastic behavi­or of human intracranial and extracranial arteries. J Biomech. 1980;13 (2):175–84.
  19. Карпов Р. С., Кошельская О. А., Сушкова А. С. Липидные и плейотропные эффекты атомакса (аторвастатина) у больных высокого кардиоваскулярного риска. Кардиоваскулярная терапия и профилактика. 2009;7 (8):30–35.
  20. Karalis DG, Ross AM, Vacari RM. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 2002;89 (6):667–671.
  21. Аронов Д. М. Симвастатин. – М.:Триада-Х, 2002. – 80с.
  22. Inoue I, Goto S, Mizotani K et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67 (8):863–876.
  23. Balduini W, Mazzoni E, Carloni S et al. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke. 2003;34 (8):2007–2012.
  24. Галактионов В. Г. Иммунология. – М.: Академия, 2004. – 520с.
  25. Marks V, Cantor T, Mesko D et al. Differential diagnosis by laboratory medicine. – Springer Verlag. 2002. – 234–240.
  26. Westendorp RG, Sattar N; PROSPER Study Group. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk.Arterioscler Thromb Vasc Biol. 2011;31 (10):2338–2344.
  27. Mälarstig A, Eriksson P, Hamsten A et al. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 2008;94 (6):724–729.
  28. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172 (2):144–152.
  29. Ishikawa M, Namiki A, Kubota T et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med. 2006;45 (2):51–55.
  30. Nakata M, Nagasaka S, Kusaka I et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4):implications in glycaemic control. Diabetologia. 2006;49 (8):1881–1892.
  31. Takano T, Yamakawa T, Takahashi M et al. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2006;13 (2):95–100.
  32. Sabatine MS, Wiviott SD, Morrow DA et al. High-dose atorvastatin associated with worse glycemic control:PROVE-IT TIMI-22 substudy. Circulation. 2004;110: S834.
  33. Collins R, Armitage J, Parish S et al. MRC / BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361 (9374):2005–2016.
  34. Sato H, Carvalho G, Sato T еt al. Statin intake is associated with decreased insulin sensitivity during cardiac surgery. Diabetes Care. 2012;35 (10):2095–2099.
  35. Baker WL, Talati R, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics:a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87 (1):98–107.
  36. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and prava­statin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull. 2003;26 (12):1681–1684.
  37. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus:evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103 (3):357–362.
  38. Takaguri A, Satoh K, Itagaki M et al. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 Adipocytes. J Pharmacol Sci. 2008;107 (1):80–89.
  39. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359 (21):2195–2207.
  40. Ridker PM, Pradhan A, MacFadyen JG et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial. Lancet. 2012;380 (9841):565–571.
  41. Ma T, Tien L, Fang CL et al. Statins and new-onset diabetes:a retrospective longitudinal cohort study. Clin Ther. 2012;34 (9):1977–1983.
  42. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26 (4):342–347.
  43. Chambarlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‑L1 adipocytes. FEBS Lett. 2001;507 (3):357–361.
  44. Сусеков А. В., Рожкова Т. А., Трипотень М. И. и др. Рандоми­зи­рованное исследование ФАРВАТЕР:Часть II. Эффект аторвастатина на функцию эндотелия, растяжимость и жесткость сосудистой стенки. Кардиоваскулярная терапия и профилактика. 2007;6 (3):68–75.
  45. Драпкина О., Палаткина Л., Зятенкова Е. Плейотропные эффекты статинов. Влияние на жесткость сосудов. Врач. 2012;9:5–8.
  46. Ferrier KE, Muhlmann MH, Baguet JP et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39 (6):1020–1025.
  47. Karter Y, Curgnlu A, Ertürk N et al. Effects of low and high dose of atorvastatin on arterial compliance. Jpn Heart J. 2003;44 (6):953–961.
  48. Akgullu C, Ozdemir B, Yilmaz Y et al. Effect of intensive statin the­rapy on arterial elasticity in patients with coronary artery disease. Acta Cardiol. 2008;63 (4):467–471.
  49. Ichihara A, Hayashi M, Koura Y et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19 (2):103–109.
  50. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity:a systematic review. Curr Vasc Pharmacol. 2010;8 (5):638–644.
  51. Economides PA, Caselli A, Tiani E et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab. 2004;89 (2):740–747.
  52. van Venrooij FV, van de Ree MA, Bots ML et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes:the Diabetes Atorvastatin Lipid Intervention (DALI) Study:a rando­mized, double-blind, placebo-controlled trial. Diabetes Care. 2002;25 (7):1211–1216.
  53. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J et al. Effects of the 3‑hydroxy-3‑methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101 (12):2711–2719.
  54. Lam HC, Chu CH, Wei MC et al. The effect of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med (Maywood). 2006;231 (6):1010–1015.
Koshelskaya O. A., Sushkova A. S., Suslova T. E. et al. Long-term atorvastatin therapy in patients with ischemic heart disease: effect on glycemia and local vascular stiffness. Russian Heart Journal. 2013;12(4):223-229

To access this material please log in or register

Register Authorize
Ru En